Key result
Alzheimer's disease patients exhibited higher PAF-AH activity, higher ox-LDL levels, and diminished PON1 activity compared to matched controls, correlating with disease severity.
Case-Control (n=83)
Alzheimer's disease patients have altered lipid metabolism enzyme activities (higher PAF-AH, lower PON1) associated with higher oxidized LDL levels, potentially contributing to systemic oxidative stress and inflammation.
May indicate oxidative lipid dysregulation in Alzheimer's; hypothesis-generating and leaves open causal or therapeutic implications.
Alzheimer's disease (AD) is associated with oxidative damage of low density lipoproteins (ox-LDL). In order to investigate whether higher levels of ox-LDL are related to alterations of the activity of enzymes involved in lipid metabolism, we studied the activity of paraoxonase-1 (PON1) and platelet activating factor acetylhydrolase (PAF-AH) in AD patients and the relationship between biochemical markers and severity of the disease. Levels of ox-LDL, PON1 (paraoxonase, arylesterase, and lactonase activities), and PAF-AH activity were evaluated in plasma from 49 patients affected by AD and from 34 control subjects matched for gender and age. Our results demonstrated alterations in the activities of PON1 and PAF-AH in AD patients compared to controls and showed, for the first time, a relationship between the activities of these enzymes, ox-LDL levels, and severity of the disease. A significant negative correlation was observed between the ratio PON1/PAF-AH and ox-LDL. Whatever the causes that contribute to a systemic oxidative stress in AD, our results have shown that AD patients exhibit higher PAF-AH activity than control subjects and higher ox-LDL. This phenomenon, in combination with diminished PON1 in these patients and, consequently, the relatively lower ratio PON1/PAF-AH activity, could contribute to inflammation and oxidative stress of plasma lipoproteins.
No takes yet. Share an insight, caveat, or question.
Bacchetti et al. (2015) conducted a case-control in Alzheimer's disease (n=83). Alzheimer's disease vs. Control subjects was evaluated on Levels of ox-LDL, PON1, and PAF-AH activity. Alzheimer's disease patients exhibited higher PAF-AH activity, higher ox-LDL levels, and diminished PON1 activity compared to matched controls, correlating with disease severity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: